Skip to main content
Clinical Trials/CTRI/2022/01/039469
CTRI/2022/01/039469
Not yet recruiting
Phase 4

A randomized controlled trial to assess the effect of riboflavin supplementation with antidepressant treatment in persons with major depressive disorder.

This has been submitted to DST for funding0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified
Sponsor
This has been submitted to DST for funding
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
This has been submitted to DST for funding

Eligibility Criteria

Inclusion Criteria

  • Subject of age 18\-55 years of either gender.
  • Patients of MDD diagnosed clinically who have not started /within 15 days of antidepressant treatment
  • Patients who are prescribed any of the antidepressants (SSRI/SNRI) as monotherapy by the psychiatrist
  • Patients who can read and understand.
  • Patients who are willing to participate and give consent.

Exclusion Criteria

  • Pregnant or seeking pregnancy, lactating women
  • Patients suffering from any chronic disease like cardiac diseases, respiratory diseases, liver disease, malignancy, peptic ulcer etc, which are known to affect inflammatory or neurodegenerative markers.
  • Associated neurological diseases other than depression
  • Progressive brain diseases like alzheimers disease, parkinsons disease, multiple sclerosis.

Outcomes

Primary Outcomes

Not specified

Similar Trials